In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...